Welcome to our dedicated page for Histogen news (Ticker: HSTO), a resource for investors and traders seeking the latest updates and insights on Histogen stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Histogen's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Histogen's position in the market.
Histogen Inc. (NASDAQ: HSTO) announces its participation as a presenting company at BIO Digital 2020, scheduled from June 8-12, 2020. This follows the completion of its merger with Conatus Pharmaceuticals. Currently, Histogen is conducting a Phase 1b/2a clinical trial for its lead product, HST 001, targeting male pattern hair loss. The company also anticipates advancements in HST 002, a novel dermal filler, and HST 003 for joint cartilage regeneration. Presentation details will be available on-demand post-event.
Histogen Inc. (NASDAQ: HSTO) has initiated its Phase 1b/2a clinical trial for HST 001, targeting androgenic alopecia in men. This study, enrolling 36 subjects, will assess safety and efficacy indicators such as hair count and density. With dosing at weeks 0, 6, and 12, top-line results are expected by Q4 2020. HST 001 aims to offer a transformative treatment by promoting new hair growth rather than just reducing hair loss, utilizing enriched growth factors. This milestone follows Histogen's recent Nasdaq listing.